Operationalization of Cancer Care in R/R Multiple Myeloma

Understanding Risks and Training Needs for Outpatient Bispecific Usage

During a Targeted Oncology™ Case-Based Roundtable™ event, Robert Mancini, PharmD, BCOP, FHOPA, discussed the various approved bispecific T-cell engagers and gave guidance for healthcare professionals, patients, and caregivers related to adverse event management. This is the second of 2 articles based on this event.

Developing Standard Operating Procedures for Using Bispecific Agents

During a Case-Based Roundtable event, Robert Mancini, PharmD, BCOP, FHOPA, discusses his experience setting up procedures for administering bispecific T-cell engagers for a large community oncology practice. This is the first of 2 articles based on this event.

Tolerability of Teclistamab Improved with Step-Up Dosing

In a discussion with Targeted Oncology, David Dingli, MD, PhD, looks at how the use of step-up dosing with tecalistimab helped avoid many serious adverse events.